Verona Pharma

Verona Pharma plc is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as COPD, cystic fibrosis and asthma. The Company is listed on the Nasdaq Global Market in the United States under the VRNA ticker and on the London Stock Exchange in the United Kingdom under the VRP.L ticker. Read more here about Verona Pharma's science and innovative therapeutics.

Investor & Analyst R&D Forum London 2019


Latest press releases

7 May 2019

Result of AGM
LONDON, May 07, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage…

7 May 2019

Verona Pharma plc Operational Update and Financial Results for the Three Months Ended March 31, 2019
Nebulized ensifentrine as add-on to dual…


Watch our latest videos about COPD and RPL554

Our breakthrough lead product, ensifentrine (RPL554), is first-in-class. It offers a unique, dual mechanism of action unlike any other type of drug currently available or in development for respiratory diseases


Current share price


0.00 (0.00%)



-0.22 (-3.59%)


Contact us

Verona Pharma plc
3 More London Riverside
London SE1 2RE
United Kingdom

T: +44 (0)203 283 4200



Registered address
One Central Square
Cardiff CF10 1FS
United Kingdom

US Investor relations contact
Westwicke, an ICR Company
T: +1 203 919 7905

European Investor relations contact
Optimum Strategic Communications
T: +44 (0)203 922 0891

Nominated adviser and broker
Nplus1 Singer Advisory LLP
One Bartholomew Lane
London EC2N 2AX
United Kingdom

T: +44 (0)203 283 4200


Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us